Paper Details

  1. Home
  2. Paper Details

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders.

Author: CerwinkaWolfgang H, ElmoreJames M, KayeJonathan D, KirschAndrew J, SmithEdwin A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Epsilon aminocaproic acid (EACA) is a drug used to treat refractory hematuria in adults, but its use in children is not well-established. This study presents initial experience using EACA for intractable hematuria in children after other measures failed, and proposes an algorithm for its administration in children.
Paper Details　
Original Abstract of the Article :
Gross, intractable hematuria is rare in children. Although the role of epsilon aminocaproic acid in the management of refractory hematuria is well established in the adult population, few data exist about its use in children for this indication. We present our initial experience with epsilon aminoca...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.juro.2010.05.020

データ提供：米国国立医学図書館（NLM）

Epsilon Aminocaproic Acid: A Potential Oasis in the Desert of Intractable Hematuria

This study explores the challenging terrain of intractable upper tract hematuria, a condition characterized by persistent bleeding from the kidneys or ureters. It delves into the use of epsilon aminocaproic acid (EACA), a medication that helps stop bleeding, as a treatment option for children with hematological disorders facing this persistent problem.

EACA Shows Promise, But More Research Needed

The study found that EACA was effective in stopping intractable hematuria in children, offering a potential oasis of relief for these patients. The authors emphasize the importance of carefully administering EACA, particularly in children, and recommend an algorithm for its use. While EACA offers promise, more research is needed to understand its full potential and to refine its application in this specific population.

Navigating the Desert of Hematological Disorders: Finding Relief and Managing Bleeding

This study sheds light on the potential benefits of EACA for children facing intractable hematuria. It emphasizes the importance of careful monitoring and individualized treatment plans. As with any medical intervention, a collaborative journey between healthcare professionals and families is crucial to navigate the complex landscape of hematological disorders.

Dr. Camel's Conclusion

This research explores the potential of EACA as a treatment for intractable hematuria in children with hematological disorders. While EACA offers promise, further research is essential to optimize its use and ensure safe and effective treatment for this challenging condition.
Date :
  1. Date Completed 2010-09-13
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

20650477

DOI: Digital Object Identifier

10.1016/j.juro.2010.05.020

Related Literature

Article Analysis
・Side Effects of aminocaproic acid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.